NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free MEIP Stock Alerts $3.06 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$3.06▼$3.1950-Day Range$3.05▼$4.2652-Week Range$3.01▼$7.97Volume17,147 shsAverage Volume21,749 shsMarket Capitalization$20.39 millionP/E Ratio1.03Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get MEI Pharma alerts: Email Address MEI Pharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside128.8% Upside$7.00 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainability-0.78Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $3.24 to ($4.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.77 out of 5 starsMedical Sector1321st out of 5,430 stocksPharmaceutical Preparations Industry535th out of 2,526 stocks 3.0 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMEI Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.34% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently increased by 167.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMEI Pharma has received a 71.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for MEI Pharma is -0.78. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for MEI Pharma this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added MEI Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to decrease in the coming year, from $3.24 to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is 1.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.61.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is 1.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 263.84.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.See his shocking evidence in this new report About MEI Pharma Stock (NASDAQ:MEIP)MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Read More MEIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEIP Stock News HeadlinesApril 29, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP)April 18, 2024 | insidermonkey.com5 Cheap Penny Stocks to Buy According to AnalystsMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 11, 2024 | msn.comMEI Pharma shelves plans for a second return of capitalApril 11, 2024 | businesswire.comMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344April 11, 2024 | businesswire.comMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsApril 10, 2024 | businesswire.comMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumMarch 26, 2024 | finance.yahoo.comMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 20, 2024 | stocknews.com3 Pharma Stocks Outperforming the CompetitionMarch 3, 2024 | investing.comMEI Pharma Inc (MEIP)February 29, 2024 | seekingalpha.comMEIP MEI Pharma, Inc.February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 13, 2024 | finance.yahoo.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 13, 2024 | finance.yahoo.comMEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue EstimatesFebruary 13, 2024 | businesswire.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 8, 2024 | wsj.comMEI Pharma Inc.February 8, 2024 | finance.yahoo.comIs MEI Pharma (MEIP) Attractively Priced?January 18, 2024 | forbes.comAcceleron PharmaJanuary 16, 2024 | finance.yahoo.comMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024December 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP), Short Interest ReportDecember 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and DatesDecember 11, 2023 | finance.yahoo.comMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023November 16, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)November 14, 2023 | morningstar.comMEI Pharma Inc MEIPNovember 9, 2023 | finance.yahoo.comMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsSee More Headlines Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/04/2024Next Earnings (Estimated)5/09/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees46Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+128.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.97 Trailing P/E Ratio1.03 Forward P/E Ratio0.94 P/E GrowthN/ANet Income$-31,840,000.00 Net Margins39.06% Pretax Margin27.32% Return on Equity39.72% Return on Assets18.26% Debt Debt-to-Equity RatioN/A Current Ratio8.23 Quick Ratio8.23 Sales & Book Value Annual Sales$72.65 million Price / Sales0.28 Cash FlowN/A Price / Cash FlowN/A Book Value$3.70 per share Price / Book0.83Miscellaneous Outstanding Shares6,663,000Free Float6,403,000Market Cap$20.39 million OptionableOptionable Beta0.82 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. David M. Urso B.A. (Age 60)Esq., J.D., CEO, President & Director Comp: $748.46kDr. Richard G. Ghalie M.D. (Age 66)MBA, Chief Medical Officer Comp: $627.76kMr. Justin J. File (Age 54)CFO & Corporate Secretary Ms. Yomara Gomez-NaidenSenior Vice President of Operations & QualityMs. Nicole Chyoko IidaVice President of Legal AffairsMs. Anne FreseChief People OfficerDr. Robert D. Mass (Age 70)Strategic Advisor Comp: $201.68kMr. David A. Walsey J.D.L.L.M., Senior Vice President of Corporate AffairsMore ExecutivesKey CompetitorsAlaunos TherapeuticsNASDAQ:TCRTSol-Gel TechnologiesNASDAQ:SLGLSynlogicNASDAQ:SYBXOnconova TherapeuticsNASDAQ:ONTXBioVieNASDAQ:BIVIView All CompetitorsInsiders & InstitutionsCable Car Capital LLCBought 611,440 shares on 2/20/2024Ownership: 9.181%National Bank of Canada FIBought 6,000 shares on 2/6/2024Ownership: 0.090%Anson Funds Management LpBought 48,060 shares on 9/22/2023Total: $329,211.00 ($6.85/share)Anson Funds Management LpBought 120,000 shares on 9/20/2023Total: $721,200.00 ($6.01/share)View All Insider TransactionsView All Institutional Transactions MEIP Stock Analysis - Frequently Asked Questions Should I buy or sell MEI Pharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares. View MEIP analyst ratings or view top-rated stocks. What is MEI Pharma's stock price target for 2024? 1 Wall Street research analysts have issued 12 month price objectives for MEI Pharma's shares. Their MEIP share price targets range from $7.00 to $7.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 128.8% from the stock's current price. View analysts price targets for MEIP or view top-rated stocks among Wall Street analysts. How have MEIP shares performed in 2024? MEI Pharma's stock was trading at $5.80 at the beginning of 2024. Since then, MEIP shares have decreased by 47.2% and is now trading at $3.06. View the best growth stocks for 2024 here. Are investors shorting MEI Pharma? MEI Pharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 20,900 shares, an increase of 167.9% from the March 31st total of 7,800 shares. Based on an average daily trading volume, of 21,200 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.3% of the company's stock are short sold. View MEI Pharma's Short Interest. When is MEI Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MEIP earnings forecast. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) issued its earnings results on Tuesday, February, 13th. The company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.46) by $0.20. MEI Pharma had a net margin of 39.06% and a trailing twelve-month return on equity of 39.72%. How often does MEI Pharma pay dividends? What is the dividend yield for MEI Pharma? MEI Pharma announced a dividend on Monday, November 6th. Investors of record on Friday, November 17th will be paid a dividend of $1.75 per share on Wednesday, December 6th. The ex-dividend date is Thursday, November 16th. Read our dividend analysis for MEIP. When did MEI Pharma's stock split? Shares of MEI Pharma reverse split on the morning of Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), OPKO Health (OPK), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MEIP) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.